JP2004532823A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532823A5 JP2004532823A5 JP2002571500A JP2002571500A JP2004532823A5 JP 2004532823 A5 JP2004532823 A5 JP 2004532823A5 JP 2002571500 A JP2002571500 A JP 2002571500A JP 2002571500 A JP2002571500 A JP 2002571500A JP 2004532823 A5 JP2004532823 A5 JP 2004532823A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- compound
- disorder
- alkyl
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 21
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 208000015114 central nervous system disease Diseases 0.000 claims 4
- 229940086609 Lipase inhibitor Drugs 0.000 claims 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 238000011282 treatment Methods 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 2
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 2
- 125000005110 aryl thio group Chemical group 0.000 claims 2
- 125000004104 aryloxy group Chemical group 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical group CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims 2
- 229960001243 orlistat Drugs 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 231100000331 toxic Toxicity 0.000 claims 2
- 230000002588 toxic effect Effects 0.000 claims 2
- XBEZLGGEPAITRO-ZDUSSCGKSA-N (4R)-4-methyl-2,3-dihydro-1H-pyrazino[1,2-a]indole-4-carbonitrile Chemical compound C[C@@]1(CNCC2=CC3=CC=CC=C3N21)C#N XBEZLGGEPAITRO-ZDUSSCGKSA-N 0.000 claims 1
- KYWYASJHTQNPQN-SNVBAGLBSA-N (4r)-4,6-dimethyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=CC(C)=C2N3[C@H](C)CNCC3=CC2=C1 KYWYASJHTQNPQN-SNVBAGLBSA-N 0.000 claims 1
- HAZWRUAJTCVCEE-MRVPVSSYSA-N (4r)-4-methyl-6-(trifluoromethyl)-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=CC(C(F)(F)F)=C2N3[C@H](C)CNCC3=CC2=C1 HAZWRUAJTCVCEE-MRVPVSSYSA-N 0.000 claims 1
- IZBGCWZNRUPEDO-LLVKDONJSA-N (4r)-4-methyl-6-thiophen-2-yl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C([C@H](N1C2=3)C)NCC1=CC2=CC=CC=3C1=CC=CS1 IZBGCWZNRUPEDO-LLVKDONJSA-N 0.000 claims 1
- FVONZVAYLZSBOJ-SECBINFHSA-N (4r)-6-ethyl-8-fluoro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C2CNC[C@@H](C)N2C2=C1C=C(F)C=C2CC FVONZVAYLZSBOJ-SECBINFHSA-N 0.000 claims 1
- WCCMHJIGZQDECL-SECBINFHSA-N (4r)-6-fluoro-4,7-dimethyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C(C)C(F)=C2N3[C@H](C)CNCC3=CC2=C1 WCCMHJIGZQDECL-SECBINFHSA-N 0.000 claims 1
- QCCLCOBTVCROQM-MRVPVSSYSA-N (4r)-7-chloro-4-methyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound C1=C(Cl)C=C2N3[C@H](C)CNCC3=CC2=C1 QCCLCOBTVCROQM-MRVPVSSYSA-N 0.000 claims 1
- PLPARSCPGGUWDI-SECBINFHSA-N (4r)-8-fluoro-4,7-dimethyl-1,2,3,4-tetrahydropyrazino[1,2-a]indole Chemical compound FC1=C(C)C=C2N3[C@H](C)CNCC3=CC2=C1 PLPARSCPGGUWDI-SECBINFHSA-N 0.000 claims 1
- 206010001488 Aggression Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- 206010020710 Hyperphagia Diseases 0.000 claims 1
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010061296 Motor dysfunction Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000027626 Neurocognitive disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010034912 Phobia Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 201000010064 diabetes insipidus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000009941 intracranial hypertension Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 201000000484 premenstrual tension Diseases 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0106177.9A GB0106177D0 (en) | 2001-03-13 | 2001-03-13 | Piperazine derivatives |
| PCT/EP2002/002443 WO2002072584A2 (en) | 2001-03-13 | 2002-03-06 | Tetrahydro-pyrazino (1,2-a) indoles for the treatment of central nervous disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004532823A JP2004532823A (ja) | 2004-10-28 |
| JP2004532823A5 true JP2004532823A5 (enExample) | 2005-07-21 |
| JP4230225B2 JP4230225B2 (ja) | 2009-02-25 |
Family
ID=9910578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002571500A Expired - Fee Related JP4230225B2 (ja) | 2001-03-13 | 2002-03-06 | ピペラジン誘導体 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6844345B2 (enExample) |
| EP (1) | EP1370561B1 (enExample) |
| JP (1) | JP4230225B2 (enExample) |
| KR (1) | KR100618748B1 (enExample) |
| CN (1) | CN1245405C (enExample) |
| AR (1) | AR035945A1 (enExample) |
| AT (1) | ATE422498T1 (enExample) |
| AU (1) | AU2002304833B2 (enExample) |
| BR (1) | BR0208111A (enExample) |
| CA (1) | CA2438596C (enExample) |
| DE (1) | DE60231107D1 (enExample) |
| ES (1) | ES2320739T3 (enExample) |
| GB (1) | GB0106177D0 (enExample) |
| GT (1) | GT200200048A (enExample) |
| MX (1) | MXPA03008338A (enExample) |
| PA (1) | PA8540801A1 (enExample) |
| PE (1) | PE20021043A1 (enExample) |
| UY (1) | UY27204A1 (enExample) |
| WO (1) | WO2002072584A2 (enExample) |
| ZA (1) | ZA200306613B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6762132B1 (en) * | 2000-08-31 | 2004-07-13 | Micron Technology, Inc. | Compositions for dissolution of low-K dielectric films, and methods of use |
| AU2003243089B2 (en) | 2002-06-19 | 2010-01-07 | Biovitrum Ab (Publ) | Novel compounds, their use and preparation |
| CL2004000826A1 (es) | 2003-04-25 | 2005-03-04 | Pfizer | Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129 |
| JP4917018B2 (ja) * | 2004-05-03 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 選択的アンドローゲン受容体モジュレーター（ｓａｒｍｓ）としての新規インドール化合物 |
| WO2006022420A1 (ja) | 2004-08-25 | 2006-03-02 | Takeda Pharmaceutical Company Limited | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| DE602006017741D1 (de) * | 2005-11-18 | 2010-12-02 | Hoffmann La Roche | Azaindol-2-carboxamid-derivate |
| ATE448230T1 (de) * | 2005-12-09 | 2009-11-15 | Hoffmann La Roche | Für die behandlung von obesitas geeignete tricyclische amidderivate |
| JP5528699B2 (ja) | 2006-05-16 | 2014-06-25 | 武田薬品工業株式会社 | 縮合複素環化合物およびその用途 |
| JP5520051B2 (ja) | 2007-11-15 | 2014-06-11 | 武田薬品工業株式会社 | 縮合ピリジン誘導体およびその用途 |
| EP2254886B1 (en) | 2008-03-28 | 2016-05-25 | Nerviano Medical Sciences S.r.l. | 3,4-dihydro-2h-pyrazino[1,2-a]indol-1-one derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| EP2510949A4 (en) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | THERAPEUTICS FOR FIBROMYALGIA |
| WO2011149036A1 (ja) * | 2010-05-27 | 2011-12-01 | 国立大学法人 東京大学 | 抗炎症薬 |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| EP2825541B1 (en) | 2012-03-16 | 2016-06-22 | Vitae Pharmaceuticals, Inc. | Liver x receptor modulators |
| BR112014022780A8 (pt) | 2012-03-16 | 2021-06-15 | Vitae Pharmaceuticals Inc | composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso |
| MY185216A (en) * | 2012-08-06 | 2021-04-30 | Hoffmann La Roche | Piperazino[1,2-a]indol-ones and [1, 4]diazepino[1,2-a]indol-1-one |
| MX2015013915A (es) * | 2013-04-02 | 2015-12-11 | Hoffmann La Roche | Piperazino[1,2-a]indol-1-onas y [1,4]diazepino[1,2-a]indol-1-ona. |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| CN106317058B (zh) * | 2016-08-17 | 2018-10-02 | 广东省微生物研究所 | 化合物dichotocejpin A及其制备方法和在制备治疗糖尿病药物中的应用 |
| JOP20190239A1 (ar) | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| EP3733204A4 (en) | 2017-12-27 | 2021-09-15 | Takeda Pharmaceutical Company Limited | THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3317524A (en) * | 1965-02-04 | 1967-05-02 | American Home Prod | Substituted 1, 2, 3, 4-tetrahydro-pyrazino[1, 2-a]indoles |
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| EP0572863A1 (de) * | 1992-06-05 | 1993-12-08 | F. Hoffmann-La Roche Ag | ZNS Pyrazinoindole |
| AU3831495A (en) * | 1994-10-20 | 1996-05-15 | American Home Products Corporation | Indole derivatives useful as serotonergic agents |
| US5854245A (en) * | 1996-06-28 | 1998-12-29 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| US6004996A (en) * | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE69916288T2 (de) | 1998-08-14 | 2005-03-24 | F. Hoffmann-La Roche Ag | Lipasehemmer und chitosan enthaltende arzneimittel |
| ATE293970T1 (de) | 1998-08-14 | 2005-05-15 | Hoffmann La Roche | Lipasehemmer enthaltende pharmazeutische zusammensetzungen |
| GB9902047D0 (en) * | 1999-01-29 | 1999-03-17 | Cerebrus Ltd | Chemical compounds XI |
| AU2001283955B2 (en) * | 2000-07-31 | 2006-05-18 | F. Hoffmann-La Roche Ag | Piperazine derivatives |
-
2001
- 2001-03-13 GB GBGB0106177.9A patent/GB0106177D0/en not_active Ceased
-
2002
- 2002-03-06 MX MXPA03008338A patent/MXPA03008338A/es not_active Application Discontinuation
- 2002-03-06 JP JP2002571500A patent/JP4230225B2/ja not_active Expired - Fee Related
- 2002-03-06 CA CA002438596A patent/CA2438596C/en not_active Expired - Fee Related
- 2002-03-06 DE DE60231107T patent/DE60231107D1/de not_active Expired - Lifetime
- 2002-03-06 KR KR1020037011901A patent/KR100618748B1/ko not_active Expired - Fee Related
- 2002-03-06 BR BR0208111-3A patent/BR0208111A/pt not_active IP Right Cessation
- 2002-03-06 ES ES02732459T patent/ES2320739T3/es not_active Expired - Lifetime
- 2002-03-06 AT AT02732459T patent/ATE422498T1/de not_active IP Right Cessation
- 2002-03-06 AU AU2002304833A patent/AU2002304833B2/en not_active Ceased
- 2002-03-06 CN CNB028062876A patent/CN1245405C/zh not_active Expired - Fee Related
- 2002-03-06 EP EP02732459A patent/EP1370561B1/en not_active Expired - Lifetime
- 2002-03-06 WO PCT/EP2002/002443 patent/WO2002072584A2/en not_active Ceased
- 2002-03-07 PA PA20028540801A patent/PA8540801A1/es unknown
- 2002-03-07 US US10/092,751 patent/US6844345B2/en not_active Expired - Fee Related
- 2002-03-11 AR ARP020100877A patent/AR035945A1/es not_active Application Discontinuation
- 2002-03-12 PE PE2002000197A patent/PE20021043A1/es not_active Application Discontinuation
- 2002-03-12 UY UY27204A patent/UY27204A1/es not_active Application Discontinuation
- 2002-03-12 GT GT200200048A patent/GT200200048A/es unknown
-
2003
- 2003-08-25 ZA ZA200306613A patent/ZA200306613B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532823A5 (enExample) | ||
| JP2004505085A5 (enExample) | ||
| JP2004527467A5 (enExample) | ||
| US12497377B2 (en) | Tricyclic spiro compound | |
| JP2002523491A5 (enExample) | ||
| JP2002523508A5 (enExample) | ||
| JP2005521671A5 (enExample) | ||
| JP2002535408A5 (enExample) | ||
| JP2002523506A5 (enExample) | ||
| JP2007508361A5 (enExample) | ||
| JP2005527579A5 (enExample) | ||
| CA2422698A1 (en) | Indoline derivatives and their use as 5-ht2 receptor ligands | |
| JP2007516941A5 (enExample) | ||
| JP2002525280A5 (enExample) | ||
| CN110809472A (zh) | 用于制备苯二氮*衍生物的方法 | |
| CA2529320A1 (en) | Benzazepine derivatives useful for the treatment of 5ht2c receptor associated diseases | |
| RU2001108570A (ru) | Пирролоиндолы, пиридиноиндолы и азепиноиндолы в качестве агонистов 5-нт2с | |
| JP2003507366A5 (enExample) | ||
| JP2007508360A5 (enExample) | ||
| JP2003507367A5 (enExample) | ||
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| ATE547417T1 (de) | Dihydropyrimidinverbindungen und ihre verwendungen bei der herstellung von medikamenten zur behandlung und prävention antiviraler krankheiten | |
| JP2006507220A5 (enExample) | ||
| RU2010119458A (ru) | 1,3,5-тризамещенное производное триазола | |
| HRP20100573T1 (hr) | Triazolopiridinkarboksamidni derivati, njihovo dobivanje i njihova upotreba u terapiji |